During the past decade, Institut Catala d'Oncologia conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 15 clinical trials were completed, i.e. on average, 25.9% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 12 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut Catala d'Oncologia" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 7 trials, followed by "Incyte Corporation" with 7 trials sponsored, "Janssen Research & Development, LLC" with 6 trials sponsored, "PETHEMA Foundation" with 4 trials sponsored and "Seagen Inc." with 4 trials sponsored. Other sponsors include 44 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Catala d'Oncologia" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator and "Amgen" with 1 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Institut Catala d'Oncologia" are "Carcinoma, Non-Small-Cell Lung" (4 trials), "Multiple Myeloma" (4 trials), "Breast Cancer" (3 trials), "Prostatic Neoplasms" (3 trials) and "Bladder Cancer" (2 trials). Many other conditions were trialed in "Institut Catala d'Oncologia" in a lesser frequency.

Most popular intervention types in "Institut Catala d'Oncologia" are "Drug" (67 trials), "Biological" (11 trials), "Radiation" (4 trials), "Procedure" (3 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Pembrolizumab" (7 trials), "Prednisone" (5 trials), "Bortezomib" (4 trials) and "Dexamethasone" (4 trials). Other intervention names were less common.

The vast majority of trials in "Institut Catala d'Oncologia" are 64 trials for "All" genders, 7 trials for "Male" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Institut Catala d'Oncologia". undefined are not yet recruiting, 22 are recruiting, 23 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Institut Catala d'Oncologia, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Institut Catala d'Oncologia, 9 "Phase 1" clinical trials were conducted, 41 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".